Time to first exacerbation"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"8
|*||SOC=standard of care (regular treatment with high-dose inhaled corticosteroid and at least 1 other controller with or without oral corticosteroids).|
Study Description: MENSA (Trial 2)"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"8 (Trial 2)
Design: 32-week study comparing treatment with NUCALA or placebo in 576 patients with severe asthma with an eosinophilic phenotype (identified by blood eosinophil counts ≥150 cells/μL at initiation of treatment [within 6 weeks of dosing] or ≥300 cells/μL in the past 12 months).
Primary endpoint: Frequency of exacerbations.
Secondary endpoint: Included frequency of exacerbations requiring hospitalization and/or ED visits.
Exacerbation definition: Exacerbations of asthma were defined as the worsening of asthma that required use of oral/systemic corticosteroids and/or hospitalization and/or ED visits; for patients requiring maintenance oral/systemic corticosteroids, exacerbations were defined as at least double the existing maintenance dose for at least 3 days.